Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Prostate Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers

NCT01287845
View directory record Official record
Conditions
Diagnostic Imaging
Interventions
BAY1075553
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 21, 2026, 8:14 PM EDT
Active, not recruiting No phase listed Observational

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401
View directory record Official record
Conditions
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
147
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

NCT01326312
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758 1000mg, Lupron Depot, GTx-758 2000mg
Drug
Lead sponsor
GTx
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
Phoenix, Arizona • La Mesa, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

NCT00996502
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, Erlotinib, Prednisone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer

NCT00869739
View directory record Official record
Conditions
Cancer Survivor, Depression, Gastrointestinal Complications, Male Erectile Disorder, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Urinary Complications
Interventions
telephone-based intervention, educational intervention, partner-assisted coping skills training, questionnaire administration, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
East Carolina University
Other
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Efficacy of Massage for the Treatment of Cancer-Related Fatigue (CRF) in Prostate Cancer Survivors

NCT03187275
View directory record Official record
Conditions
Cancer-related Problem/Condition
Interventions
Swedish Massage Therapy, Light Touch Intervention
Other
Lead sponsor
Emory University
Other
Eligibility
45 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

NCT00005857
View directory record Official record
Conditions
Prostate Cancer
Interventions
trastuzumab, docetaxel
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

NCT01420861
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
San Bernardino, California • Jeffersonville, Indiana • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 21, 2026, 8:14 PM EDT
Active, not recruiting Not applicable Interventional

Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at The James

NCT01643954
View directory record Official record
Conditions
Prostate Cancer
Interventions
robotic radical prostatectomy
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1,531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

NCT00712829
View directory record Official record
Conditions
Prostate Cancer
Interventions
123-I-MIP-1072, 123-I-MIP-1095
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

NCT00004929
View directory record Official record
Conditions
Prostate Cancer
Interventions
MUC-2-KLH vaccine, QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 21, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Understanding of Genetics by Men at Risk for Prostate Cancer

NCT04550845
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focus group analyses
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 95 Years · Male only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Not listed Phase 3 Interventional

I-125 Versus Pd-103 for Low Risk Prostate Cancer

NCT00494039
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radioactive seed implant to prostate
Procedure
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
40 Years to 80 Years · Male only
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2007 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
42
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

NCT00333502
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • Farmington, New Mexico
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional

UroLift System With SAbR for Prostate Cancer and BPH

NCT05311527
View directory record Official record
Conditions
Prostate Cancer
Interventions
Urolift, SABR
Device · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

NCT05678322
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional

CHESS Caregivers Study: Web-based Support for Informal Caregivers in Cancer

NCT00214162
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Comprehensive Health Enhancement Support System, computer with internet
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 21, 2026, 8:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

NCT00453661
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer
Interventions
Questionnaire, Patient Navigator (PN)
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years and older
Enrollment
2,472 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00483561
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gefitinib plus etoposide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 21, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT05915442
View directory record Official record
Conditions
Oligometastatic Prostate Cancer
Interventions
Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Catherine Spina
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional

Hypofractionated Proton Beam Therapy for Localized Prostate Cancer

NCT01950351
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Active, not recruiting Not applicable Interventional

Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II)

NCT03999151
View directory record Official record
Conditions
Prostate Cancer
Interventions
Exercise and Diet
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 8:14 PM EDT